{"id":"NCT03073200","sponsor":"Eli Lilly and Company","briefTitle":"Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis","officialTitle":"Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-28","primaryCompletion":"2019-02-07","completion":"2021-03-23","firstPosted":"2017-03-08","resultsPosted":"2020-03-17","lastUpdate":"2021-09-27"},"enrollment":201,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Ixekizumab","otherNames":["LY2439821"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Etanercept","otherNames":[]}],"arms":[{"label":"Ixekizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Open-Label Etanercept","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Participants With a â‰¥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab)","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo","deltaMin":25,"sd":null},{"arm":"Ixekizumab","deltaMin":88.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":69,"countries":["United States","Argentina","Canada","Czechia","France","Germany","Hungary","Mexico","Netherlands","Poland","Puerto Rico","Russia","Spain"]},"refs":{"pmids":["35416908"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/2xPbhh7bJKOwooYG2OKg6c"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":56},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Injection site reaction","Headache","Pharyngitis"]}}